

PATENT
Docket No. 3816-4000
Facsimile

- Sub H4
- (b) cells expressing the target human antigen or a fragment thereof, where the cells are optionally labelled; and
- (c) a soluble target human antigen or a fragment thereof, the target human antigen being optionally labeled;

a second step selected from the group consisting of:

- (ii) removing by washing off the display vehicles that are not bound to (a) or (b) and subsequently eluting the display vehicles that are bound to (a) or (b), and
- (iii) positively enriching the target human antigen-bound display vehicles from the suspension of cells expressing the target human antigen (b) or from the target human antigen in (c);

the said isolated display vehicles comprising the desired anti-human antigen receptor bound to the target human antigen being optionally multiplied by replication and subjected to further rounds of in vitro selection steps (i) to (iii).

- 22 Sub H12
28. An anti-human antigen receptor obtained by the method according to claim 17, said anti human antigen being characterized in that it is derived from human sequences and is specific for the native human 17-1A antigen.

- 93 Sub H13
31. The anti-human antigen receptor of claim 29 recognizing an epitope of the extracellular domain of the 17-1A antigen comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 32, 34, 35, 80, 81, 98, 100.

A marked-up copy of the amended claims is attached as the Appendix.

REMARKS

Claims 10, 28 and 31 were amended in the response dated November 27, 2001. However, several inadvertent errors were made in the amendment. This amendment is submitted to correct the inadvertent errors. Support for the amendment of claims 10, and 28 are to be found in the originally filed claims and in the specification at page 10, 4th paragraph; page 11, paragraph 3rd paragraph. Claim 31 has been amended to provide the proper Markush format. Support for the